FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292787571> ?p ?o ?g. }

• W4292787571 endingPage "31537" @default.
• W4292787571 startingPage "31529" @default.
• W4292787571 abstract "Patients with prostate-specific membrane antigen (PSMA)-positive tumors can benefit from PSMA-targeted therapy; thus, we have constructed a phage-displayed synthetic antibody library for the production of novel PSMA antibodies with superior PSMA-targeting ability, favoring clinical management. The binding affinities of anti-PSMA antibodies were verified by an enzyme-linked immunosorbent assay (ELISA). Several in vitro and in vivo experiments, including cellular uptake, internalization, and cytotoxicity studies, micro single photon emission computed tomography (microSPECT)/CT, and biodistribution studies, were performed to select the most promising antibody among six different antibodies. The results showed the target affinities of our antibodies in the ELISA assays (7A, 8C, 8E, and 11A) were comparable to the existing antibodies (J591). The half-maximal effective concentrations of 7A, 8C, 8E, 11A, and J591 were 2.95, 6.64, 5.50, 2.08, and 4.79, respectively. The radiochemical yield of 111In-labeled antibodies ranged from 30% to 50% with high radiochemical purity (>90%). In the cellular uptake studies, the accumulated radioactivity of 111In-J591, 111In-7A, and 111In-11A increased over time. The internalized percentage of 111In-11A was the highest (32.14% ± 2.06%) at 48 h after incubation, whereas that of 111In-J591 peaked at 22.43% ± 4.38% at 24 h and dropped to 13.52% ± 3.03% at 48 h postincubation. Twenty-four hours after injection, radioactivity accumulation appeared in the LNCaP xenografts of the mice injected with 111In-11A, 111In-8E, 111In-7A, and 111In-J591 but not in the xenografts of the 111In-8C-injected group. Marked liver uptake was noticed in all groups except the 111In-11A-injected group. Moreover, the killing effect of 177Lu-11A was superior to that of 177Lu-J591 at low concentrations. In conclusion, we successfully demonstrated that 11A IgG owned the most optimal biological characteristics among several new anti-PSMA antibodies and it can be an excellent PSMA-targeting component for the clinical use." @default.
• W4292787571 created "2022-08-23" @default.
• W4292787571 creator A5009638476 @default.
• W4292787571 creator A5023615043 @default.
• W4292787571 creator A5026627325 @default.
• W4292787571 creator A5049943358 @default.
• W4292787571 creator A5067527887 @default.
• W4292787571 creator A5081279781 @default.
• W4292787571 date "2022-08-23" @default.
• W4292787571 modified "2023-10-16" @default.
• W4292787571 title "Tumor-Targeting Ability of Novel Anti-Prostate-Specific Membrane Antigen Antibodies" @default.
• W4292787571 cites W1544486867 @default.
• W4292787571 cites W1904705300 @default.
• W4292787571 cites W1977316337 @default.
• W4292787571 cites W2017843343 @default.
• W4292787571 cites W2093483406 @default.
• W4292787571 cites W2105337740 @default.
• W4292787571 cites W2129389720 @default.
• W4292787571 cites W2133312453 @default.
• W4292787571 cites W2134247556 @default.
• W4292787571 cites W2155421560 @default.
• W4292787571 cites W2163559554 @default.
• W4292787571 cites W2226317100 @default.
• W4292787571 cites W2241372383 @default.
• W4292787571 cites W2396813794 @default.
• W4292787571 cites W2509704187 @default.
• W4292787571 cites W2530907197 @default.
• W4292787571 cites W2625293218 @default.
• W4292787571 cites W2731595036 @default.
• W4292787571 cites W2888184127 @default.
• W4292787571 cites W2889718222 @default.
• W4292787571 cites W2898599991 @default.
• W4292787571 cites W2965182578 @default.
• W4292787571 cites W2996077865 @default.
• W4292787571 cites W3007389375 @default.
• W4292787571 cites W3029012726 @default.
• W4292787571 cites W3128646645 @default.
• W4292787571 cites W3171439056 @default.
• W4292787571 cites W4256580138 @default.
• W4292787571 cites W974281930 @default.
• W4292787571 doi "https://doi.org/10.1021/acsomega.2c04230" @default.
• W4292787571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36092556" @default.
• W4292787571 hasPublicationYear "2022" @default.
• W4292787571 type Work @default.
• W4292787571 citedByCount "0" @default.
• W4292787571 crossrefType "journal-article" @default.
• W4292787571 hasAuthorship W4292787571A5009638476 @default.
• W4292787571 hasAuthorship W4292787571A5023615043 @default.
• W4292787571 hasAuthorship W4292787571A5026627325 @default.
• W4292787571 hasAuthorship W4292787571A5049943358 @default.
• W4292787571 hasAuthorship W4292787571A5067527887 @default.
• W4292787571 hasAuthorship W4292787571A5081279781 @default.
• W4292787571 hasBestOaLocation W42927875712 @default.
• W4292787571 hasConcept C121608353 @default.
• W4292787571 hasConcept C126322002 @default.
• W4292787571 hasConcept C139770010 @default.
• W4292787571 hasConcept C147483822 @default.
• W4292787571 hasConcept C1491633281 @default.
• W4292787571 hasConcept C150903083 @default.
• W4292787571 hasConcept C153911025 @default.
• W4292787571 hasConcept C159654299 @default.
• W4292787571 hasConcept C185592680 @default.
• W4292787571 hasConcept C202751555 @default.
• W4292787571 hasConcept C203014093 @default.
• W4292787571 hasConcept C20417620 @default.
• W4292787571 hasConcept C207001950 @default.
• W4292787571 hasConcept C2776235491 @default.
• W4292787571 hasConcept C2777807558 @default.
• W4292787571 hasConcept C2779723316 @default.
• W4292787571 hasConcept C502942594 @default.
• W4292787571 hasConcept C55493867 @default.
• W4292787571 hasConcept C71924100 @default.
• W4292787571 hasConcept C86803240 @default.
• W4292787571 hasConceptScore W4292787571C121608353 @default.
• W4292787571 hasConceptScore W4292787571C126322002 @default.
• W4292787571 hasConceptScore W4292787571C139770010 @default.
• W4292787571 hasConceptScore W4292787571C147483822 @default.
• W4292787571 hasConceptScore W4292787571C1491633281 @default.
• W4292787571 hasConceptScore W4292787571C150903083 @default.
• W4292787571 hasConceptScore W4292787571C153911025 @default.
• W4292787571 hasConceptScore W4292787571C159654299 @default.
• W4292787571 hasConceptScore W4292787571C185592680 @default.
• W4292787571 hasConceptScore W4292787571C202751555 @default.
• W4292787571 hasConceptScore W4292787571C203014093 @default.
• W4292787571 hasConceptScore W4292787571C20417620 @default.
• W4292787571 hasConceptScore W4292787571C207001950 @default.
• W4292787571 hasConceptScore W4292787571C2776235491 @default.
• W4292787571 hasConceptScore W4292787571C2777807558 @default.
• W4292787571 hasConceptScore W4292787571C2779723316 @default.
• W4292787571 hasConceptScore W4292787571C502942594 @default.
• W4292787571 hasConceptScore W4292787571C55493867 @default.
• W4292787571 hasConceptScore W4292787571C71924100 @default.
• W4292787571 hasConceptScore W4292787571C86803240 @default.
• W4292787571 hasFunder F4320322795 @default.
• W4292787571 hasFunder F4320323144 @default.
• W4292787571 hasIssue "35" @default.
• W4292787571 hasLocation W42927875711 @default.
• W4292787571 hasLocation W42927875712 @default.

• next